Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

0 seconds of 0 secondsVolume 90%

00:00

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

SGO 2021 Virtual Annual Meeting on Womens Cancer

Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated, platinum-resistant, or platinum-sensitive relapsed ovarian cancer (ID #10191).

Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer

Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all women with ovarian cancer, despite a concurrent increase in frail patients (ID #10209).

Gynecologic Cancers

COVID-19

The ASCO Post Staff

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).

Gynecologic Cancers

The ASCO Post Staff

Anthony B. Costales, MD, on Advanced Ovarian Cancer: Predicting the Benefits of Minimally Invasive Surgery

Anthony B. Costales, MD, of the Baylor College of Medicine, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy is feasible, safe, and provides similar outcomes as open surgery.

Gynecologic Cancers

The ASCO Post Staff

Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device

Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6 months, the data showed a complete pathologic response in 82% of patients with EHA and in 43% of those with EAC (ID# 10244).

Gynecologic Cancers

Genomics/Genetics

The ASCO Post Staff

Sandro Pignata, MD, PhD, on BRCA-Mutated Ovarian Cancer: Maintenance Olaparib Outcomes

Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, discusses results from the ORZORA trial, which showed the efficacy of olaparib in patients with platinum-sensitive relapsed ovarian cancer is similar, whether they have a germline or somatic BRCA mutation. This information could prove useful for clinical practice (ID #10226).

Apr

Today In Oncology

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

Related Videos

Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Anthony B. Costales, MD, on Advanced Ovarian Cancer: Predicting the Benefits of Minimally Invasive Surgery

Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device

Sandro Pignata, MD, PhD, on BRCA-Mutated Ovarian Cancer: Maintenance Olaparib Outcomes

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection

Characteristics of Nasopharyngeal Carcinoma in the United States

Grocery Store Choice Could Impact Obesity Related Cancer Mortality